Allogeneic stem cell transplantation for severe aplastic anemia: Graft rejection remains a problem


Aki S. Z. , Sucak G. T. , ÖZKURT Z. N. , YEGİN Z. A. , Yagci M., Haznedar R.

TRANSFUSION AND APHERESIS SCIENCE, vol.40, no.1, pp.5-11, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 1
  • Publication Date: 2009
  • Doi Number: 10.1016/j.transci.2008.11.007
  • Journal Name: TRANSFUSION AND APHERESIS SCIENCE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.5-11
  • Keywords: Severe aplastic anemia, Allogeneic stem cell transplantation, Rejection, Fludarabine, BONE-MARROW-TRANSPLANTATION, TERM-FOLLOW-UP, ANTITHYMOCYTE GLOBULIN, CONDITIONING REGIMEN, CYCLOPHOSPHAMIDE, FLUDARABINE, BLOOD, EXPERIENCE, FAILURE
  • Gazi University Affiliated: Yes

Abstract

We reviewed the outcome in 15 consecutive patients with severe aplastic anemia with a median age of 23 years who received matched sibling peripheral blood stein cell transplantation. Conditioning regimen was cyclophosphamide (Cy) + anti-thymocyte globulin (ATG). Cumulative incidence of transplant related mortality, graft failure, acute and chronic GVHD were 20%., 33%, 25%, and 8.3%, respectively. Conditioning with Cy only, resulted in higher rejection rate compared to Cy plus ATG (75%, versus 12.5%, p = 0.03). Eighty percent of patients are alive with a median follow-up of 19.5 (4.6-35.6) months. Two of the three patients who were re-transplanted with fludarabine had sustained donor chimerism. (C) 2008 Elsevier Ltd. All rights reserved.